sign (+) inside this box →

PTO/SB/20030

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE						
/		Application Number	10/080,435			
	SMITTAL	Filing Date	February 22, 2002			
FC	ORM	First Named Inventor	Mark G. ERLANDER			
		Group Art Unit	1645 DEC			
(to be used for all corres	spondence after initial filing)	Examiner Name	To Be Assigned			
Total Number Of Pages In Th	is Submission 6	Attorney Docket No.	Mark G. ERLANDER  1645  To Be Assigned  485772003300  apply)			
	ENCLOS	SURES (check all that	apply)			
Fee Transmittal For		signment Papers r an Application)	After Allowance Communication to Group			
Fee Attache	d Dra	awing(s)	Appeal Communication to Board of Appeals and Interferences			
Amendment / Reply	Lic	ensing-related Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
After Final	Pe	tition	Proprietary Information			
Affidavits/de		tition to Convert to a ovisional Application	Status Letter			
Extension of Time R		wer of Attorney, Revocation ange of Correspondence Ad	Other Enclosure(s) (please identify below): Return postcard			
		rminal Disclaimer	-			
. Express Abandonm	ent Request Re	quest for Refund				
Information Disclosu PTO form 1449; and		), Number of CD(s)	· 			
Certified Copy of Pri	iority Document(s) Remarks					
Response to Missing Incomplete Applicat			·			
	o Missing Parts FR 1.52 or 1.53					
SIGNATURE OF APPLICANT, ATTORNEY OR AGENT						
Firm	Kawai Lau, Registration No. 44,46 Morrison & Foerster LLP	57	·			
OF	3811 Valley Centre Drive, Suite 5	00: San Diego, CA 92130-2332	·			
Individual Name	- Landy Contact Britis, Cutter Co	,				
Signature	Fen					
Date	December 17, 2002	<del></del>				

CERTIFIC	ATE	OF I	HAR	INC F	V "EIDC	TCL	224	BAAIL	,,
CEKIIPIC	MIE.	OF I	AIMIL	.11705	I FIRS		<b>~</b> 33	ITIMIL	

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on December 17, 2002

Jose Luna

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



## CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

Assistant Commissioner for Patents, Washington, D.C. 20231, on December 17, 2002.

Jose Luna

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Mark G. ERLANDER, et al.

Serial No.:

10/080,435

Filing Date:

February 22, 2002

For:

**QUANTITATIVE** 

IMMUNOHISTOCHEMISTRY (QIHC)

Examiner: To Be Assigned

Group Art Unit: 1645

RECEIVED
DEC 2 7 2002
TECH CENTER 1800/2900

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

	I nis in	formation Disclosure Statement is submitted:							
	With	the application; accordingly, no fee or separate requirements are required.							
$\boxtimes$	Withi	Within three months of the application filing date or before mailing of a first Office							
	Actio	Action on the merits; accordingly, no fee or separate requirements are required.							
	After	receipt of a first Office Action on the merits but before mailing of a final Office							
	Action or Notice of Allowance.								
		A fee is required. A check in the amount of * is enclosed.							
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached							
		to this submission in duplicate.							
	· 🔲	A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee							
		is believed to be due.							
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the							
	issue	fee.							
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the							
		amount of * is enclosed.							
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal							
		form (PTO/SB/17 is attached to this submission in duplicate.							

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 485772003300. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: December 17, 2002

Respectfully submitted,

By:

Kawai Lau Registration No. 44,461

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-5178 Facsimile: (858) 720-5125

Form PTO-1449					Docket Number 485772003300		Application Number 10/080,435	
· •				Applicant				
IN AN APPLICATION						Mark G. ER	LANDER, et al.	
. 10	W 2 TO	se several sheets if n	necessary)	Filing Date February 22, 2	002	Group Art Unit	1645	
DEC 2 4 20					Mailing Date December 1	<b>7</b> , 2002	Pr	
ATENTA TRA	, șe j						175	CEIVE
& TRA							DEC	PIVED
			U.S. PAT	ΓENT	DOCUMENTS		TECH CENT	CEIVED
Examiner Initials	Ref. No.	Date	Document No.		Name	Class	Subclass	2 7 2002 First 600 page If Appropriate
	1.	07/1994	5,328,985	Sano	et al.	530	350	
	2.	09/1997	5,665,539	Sano	et al.	435	6	
	3.	07/1999	5,922,553	Eber	wine et al.	435	7.92	
	<b>-</b>							:
			FOREICNI	) A TUE		r.C		
F	D-C	Dete	1	AIE	Country Country	r	Subclass	Translation
Examiner Initials	Ref. No.	Date	Document No.		Country	Class	Subclass	YES NO
•	4.	08/1993	WO 93/15229	WIP	O			
			OTHE	R DC	CUMENTS	(includi	ng author, title, Dat	te, Pertinent Pages, Etc.)
Examiner Initials	Examiner Ref. Title							
Hittais	Initials No.  5. Brown et al. "Defining the Smallest Analyte Concentration An Immunoassay Can Measure" Clinical							
	Chemistry 42(6):893-903 (1996)							
	6.	Cao et al. "In-Situ Immuno-PCR to Detect Antigens" Lancet 356:1002-1003 (2000)						
	7.	Chamberlin et al. The Enzymes (Boyer, ed.) Academic Press, New York pp.87-108 (1982)						
	8. Ebersole et al. "Analyte Detection With DNA-Labeled Antibodies and Polymerase Chain Reaction" Clinical Chemistry 41(9):1371-1377 (1995)							
	9.							
	10. Hendrickson et al. "High Sensitivity Multianalyte Immunoassay Using Covalent DNA-Labeled Antibodies and Polymerase Chain Reaction" Nucleic Acids Research 23(3):522-529 (1995)							
	11.							
	12.							
	13.							
<del> </del>	14. Shweitzer et al. "Immunoassays with Rolling Circle DNA Amplification: A Versatile Platform for Ultrasensitive Antigen Detection" Proc. Natl. Acad. Sci. USA 97:10113-10119 (2000)							
EXAMI	VER:				DATE CONSI	DERED:	·	
			idered, whether or not the clude a copy of this form				line through the	citation if not in

Form PTO-1449  NEORMATION DISCLOSURE CITATION  CO IN AN APPLICATION			Docket Number 485772003300 Application Number 10/080,435		
			Applicant  Mark G. ERLANDER, et al.		
OEE 2 (Use several sheets if necessary)		Filing Date February 22, 2002	Group Art Unit 1645		
DEC 1			Mailing Date December 17, 2002		
Tree Se					
W BIK	15.	Sims et al. "Immunopolymerase Chai Detection" Analytical Biochemistry 2		Polymerase Chain Reaction for	
	16.	Zhang et al. "Cellular Immuno-PCR Detection of a Carbohydrate Tumor Marker" American Journal of Pathology 152:1427-1432 (1998)			
	17.	Zhou et al. "Universal Immuno-PCR for Ultra-Sensitive Target Protein Detection" Nucleic Acids Research 21(25):6038-6039 (1993)			

RECEIVED
DEC 2 7 2002
TECH CENTER 1600/2900

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.